Juvenile idiopathic arthritis (JIA) can affect all joints, including the temporomandibular joints (TMJs). For a long time, the TMJ was a “forgotten” joint in pediatric rheumatology, although Sir Frederick Still did comment on a small mandible in his first case series on juvenile arthritis in 1897. In recent years, more attention has been given to…
How are COVID-19 and current restrictions on physical distancing affecting rheumatologists? The Rheumatologist interviewed Karim Masri, MD, to ask how the pandemic has changed the way he and his clinic staff deliver patient care, and how these unprecedented times affect patients, staff and life outside the office. Dr. Masri is a practicing rheumatologist at Bon…
On April 7, the FDA approved an Abbreviated New Drug Application (ANDA) for Hydroxychloroquine Sulfate Tablets USP, 200 mg, for the treatment of: 1) uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; 2) chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and 3) treatment of acute and chronic…
The FDA has authorized a phase 3 clinical trial examining the safety and efficacy of tocilizumab plus standard care in patients hospitalized with COVID-19…
Afton Hassett, PsyD, offers self-care tips and resources to handle stress, avoid burnout and stay healthy while caring for others.
On April 1, UnitedHealthcare (UHC) announced updates to its Orencia policy, effective July 1, 2020. The change requires patients to fail to respond to the self-administered formulation of this drug prior to obtaining authorization for the physician-administered product. The ACR has been in communication with UHC about this policy since October 2019, when the payer…
Researchers discuss new insights into inflammation signals and mediators…
A case study of a 7-year-old girl who is eventually diagnosed with anti-MOG autoimmune encephalomyelitis highlights the necessity of a multi-disciplinary approach to inflammatory brain disease…
NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the…
PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an…